Lambert-Eaton Syndrome (LES) is primarily characterized by an autoimmune attack against presynaptic voltage-gated calcium channels (VGCCs) at the neuromuscular junction. These channels are crucial for the release of acetylcholine, the neurotransmitter responsible for triggering muscle contraction. In LES, antibodies target these channels, significantly reducing acetylcholine release, which leads to muscle weakness and fatigue.
The pathophysiology of LES includes:
- Reduced Calcium Influx: The autoimmune response against VGCCs diminishes the influx of calcium into the nerve terminal, which is necessary for the exocytosis of synaptic vesicles containing acetylcholine.
- Decreased Acetylcholine Release: With fewer calcium ions entering the nerve terminal, the release of acetylcholine is substantially reduced, leading to ineffective muscle fiber activation and consequent muscle weakness.
- Improvement with Use: Unlike other forms of muscle weakness, LES symptoms can improve with repeated muscle use. This phenomenon, known as 'facilitation,' occurs as repeated stimulation of the nerve increases the calcium ion concentration temporarily, somewhat overcoming the blockade and enhancing acetylcholine release.
